Minscalp 10% Topical Solution

Minscalp 10% Topical Solution belongs to a class of drugs known as vasodilators. It is used to promote hair growth in men with male pattern baldness.

Minscalp 10% Topical Solution should only be applied directly to the scalp area in the amount and in the way specified on the label or by your doctor. Clean and dry your scalp before using it. It may take approximately 2- 4 months before you notice any hair growth. The first growth may be soft, colourless, and barely visible. Using more than recommended will not speed up hair growth and may increase the likelihood of side effects. This medication must be used continuously to maintain hair growth. Tell your doctor if your condition does not improve or worsen after using it for 4 to 6 months.

The most common side effects of this medicine include itching, headache, excessive hair growth, rash, and dermatitis. In case of accidental application in other areas, it may result in unwanted hair growth. Rinse thoroughly with plenty of water if you get it in your eyes, mouth, or broken skin. Talk to your doctor if you are bothered by the side effects or if they do not go away.

People under 18 or over 65 should not usually use Minscalp 10% Topical Solution. It may also not be appropriate if your hair loss is due to medications (such as chemotherapy) or any nutritional deficiency. You should also not use this medicine if you have high blood pressure or use other creams or lotions to treat other scalp conditions. Talk to your doctor if you have heart disease or blood circulation problems.

• Treatment of Hair loss

Treatment of Hair loss
Minscalp 10% Topical Solution is a medicine used to treat common hereditary hair loss. It can prevent further hair loss and help hair to re-grow. It works by increasing blood flow to the hair follicles on your scalp, which prevents hair cell death and also enhances new hair growth. It is most effective for baldness or thinning at the top of the scalp but less effective at the front or for receding hairline.

Benefits are less likely if you have been bald for many years or have a large area of hair loss. Minscalp 10% Topical Solution is not suitable for sudden or unexplained hair loss. It is considered a safe medicine. There are separate products for men and women and you should follow your doctor’s instructions carefully while using Minscalp 10% Topical Solution. Regrowth of hair improves your appearance, boosts your confidence, and enhances your social life. Use it regularly to maintain hair growth and to get the maximum benefits. Consult your doctor if you notice any changes in the hair growth while using Minscalp 10% Topical Solution.

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Hairouse

• Itching
• Chest pain
• Headache
• Hypertrichosis (excessive hair growth)
• Rash
• Dermatitis
• Hypersensitivity
• Weight gain
• Fluid retention
• Tachycardia

Use this medicine in the dose and duration as advised by your doctor. Check the label for directions before use.

Minscalp 10% Topical Solution is a potassium channel opener. Its vasodilation action expands the blood vessels. Therefore, when it is applied to the scalp, it helps to increase blood flow. This increased blood flow provides more nutrition and oxygen to the hair follicles, which prevents hair cell death and also enhances new hair growth. This is how it works to treat your alopecia (hair loss).

• Wash your hands before and after application.
• It should only be applied directly to the scalp. If Minscalp 10% Topical Solution accidentally comes in contact with your eyes, nose, or mouth, flush the area thoroughly with cool tap water.
• Do not shampoo your hair or use a hairdryer for 4 hours after applying Minscalp 10% Topical Solution as it can reduce the effectiveness of the medicine.
• During the first 2 weeks of application, your hair fall may increase. This is normal and is a sign that Minscalp 10% Topical Solution is working.
• Take care that Minscalp 10% Topical Solution does not trickle down onto your face as it may cause undesirable facial hair growth.

Burkhart C, Morrell D, Goldsmith L. Dermatological Pharmacology. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. p. 1829.

Benowitz NL. Antihypertensive Agents. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. p. 179.

Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 922-24.

Chaves RG, Lamounier JA. Breastfeeding and maternal medications. J Pediatr (Rio J). 2004;80(5 Suppl):S189-S198. [Accessed 18 Mar. 2019] (online) Available from:

Minoxidil. Maidenhead, Berks: McNeil Products Ltd.; 2010 [revised 01 May 2018]. [Accessed 17 Jun. 2019]. (online) Available from:

Minoxidil. Val-de-Reuil, France: Janssen-Cilag; 2018. [Accessed 17 Jun. 2019] (online) Available from:

Drugs.com. Minoxidil topical Pregnancy and Breastfeeding Warnings. [Accessed 18 Jul. 2019] (online) Available from:

Central Drugs Standard Control Organisation (CDSCO). [Accessed 19 Mar. 2019] (online) Available from:

5% Minoxidil Topical Solution [Product Information]. New York, NY: Avacor Products LLC; 2019. [Accessed 31 Jan. 2023] (online) Available from:

2% Minoxidil Topical Solution [Product Label]. Skillman, NJ: Johnson & Johnson Healthcare Products; 2014. [Accessed 31 Jan. 2023] (online) Available from:

Minoxidil (5% w/v cutaneous solution) [Package Information Leaflet]. Athens, Greece: Target Pharma Ltd.; 2012. [Accessed 31 Jan. 2023] (online) Available from:

Minoxidil 5% cutaneous solution [Package leaflet: Information for the user]. London, UK: Careforsons Limited; 2020. [Accessed 31 Jan. 2023] (online) Available from:

Minoxidil [Information for the user]. Devon, UK: Wrafton Laboratories Limited; 2017. [Accessed 31 Jan. 2023] (online) Available from: